More specifically, these trials showed that first line treatments combining BE improved the progression free survival (PFS)—but not overall survival (OS)—of patients harboring an EGFR driver mutation in comparison with E alone [7, 9]. This evidence concerns the gene EGFR and Barrett esophagus.